Kawasaki disease natural history, complications and prognosis

Revision as of 16:52, 14 February 2020 by Sabawoon Mirwais (talk | contribs) (→‎Complications)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Kawasaki disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kawasaki disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kawasaki disease natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kawasaki disease natural history, complications and prognosis

CDC on Kawasaki disease natural history, complications and prognosis

Kawasaki disease natural history, complications and prognosis in the news

Blogs on Kawasaki disease natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Kawasaki disease natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]

Overview

If left untreated, the symptoms will eventually relent, but coronary artery aneurysms will not improve, resulting in a significant risk of death or disability due to myocardial infarction. If treated in a timely fashion, this risk can be mostly avoided and the course of illness cut short. Patients with Kawasaki disease may progress to develop long term cardiovascular illness such as coronary artery disease, and pre-mature atherosclerosis. Common complications of Kawasaki disease include vasculitis and coronary artery aneurysms. Prognosis is generally excellent and the mortality rate of patients with Kawasaki disease is approximately 2%.

Natural History, Complications, and Prognosis

Natural History

Complications

Organ and Tissue Associated Conditions
Liver
Lung
Gastrointestinal tract
Meninges
Heart
Urinary tract
Pancreas
Lymph nodes

Prognosis

  • With early treatment, rapid recovery from the acute symptoms can be expected and the risk of coronary artery aneurysms greatly reduced.
  • Untreated, the acute symptoms of Kawasaki disease are self-limited, but the risk of coronary artery involvement is much greater.
  • Patients who have had Kawasaki disease should have an echocardiogram initially every few weeks, and then every 1 - 2 years to screen for the progression of cardiac involvement.
  • Overall, about 2% of the patients die from complications of coronary vasculitis.
  • It is also not uncommon that a relapse of symptoms may occur soon after initial treatment with IVIG.
    • This usually requires re-hospitalization and retreatment. Treatment with IVIG can cause allergic and non-allergic acute reactions, aseptic meningitis, fluid overload and rarely other serious reactions.
    • Aspirin may increase the risk of bleeding from other causes and may be associated with Reye's syndrome.
    • Overall, life-threatening complications resulting from therapy for Kawasaki disease are exceedingly rare, especially compared with the risk of non-treatment.

References

  1. Kato H (September 2014). "[Natural history of Kawasaki disease vasculitis]". Nippon Rinsho (in Japanese). 72 (9): 1530–5. PMID 25518398.
  2. Belay E, Maddox R, Holman R, Curns A, Ballah K, Schonberger L (2006). "Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003". Pediatr Infect Dis J. 25 (3): 245–9. PMID 16511388.
  3. McCrindle, Brian W.; Rowley, Anne H.; Newburger, Jane W.; Burns, Jane C.; Bolger, Anne F.; Gewitz, Michael; Baker, Annette L.; Jackson, Mary Anne; Takahashi, Masato; Shah, Pinak B.; Kobayashi, Tohru; Wu, Mei-Hwan; Saji, Tsutomu T.; Pahl, Elfriede (2017). "Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association". Circulation. 135 (17): e927–e999. doi:10.1161/CIR.0000000000000484. ISSN 0009-7322.
  4. Amano S, Hazama F, Hamashima Y (July 1979). "Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes". Jpn. Circ. J. 43 (7): 633–43. PMID 41111.

Template:WH Template:WS